Introduction
============

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males worldwide and the second most common in females, with an estimated 1.4 million cases occurring in 2012 ([@b1-ol-0-0-4299]). There are no typical symptoms until the late stages of the disease, which may then include abdominal pain, hematochezia and change of stool customs. Two thirds of CRC cases are colon cancer ([@b2-ol-0-0-4299]), for which the main treatment is radical surgery. Approximately 40% of patients experience recurrence, and this is consequently the main cause of mortality among affected individuals ([@b3-ol-0-0-4299]). It has been reported that the average survival time for patients with tumor recurrence is 7 months, which can be increased to \~29.9 months when a second surgery is performed ([@b4-ol-0-0-4299]). For this reason, when treating patients with recurrent colon cancer, the main aim is to achieve a radical resection or to at least perform palliative surgery.

Neoadjuvant chemoradiotherapy is a feasible option in order to realize an R0 resection for local recurrent colon cancer. Perioperative radiation therapy and chemotherapy can also reduce the recurrence rate and prolong the survival time of patients ([@b5-ol-0-0-4299]--[@b7-ol-0-0-4299]). Irinotecan (CPT-11) has shown anti-tumor effects in multiple types of tumor is also used in the neoadjuvant chemotherapy for colon cancer ([@b8-ol-0-0-4299]). Intraperitoneal (IP) chemotherapy with CPT-11 is also applied to treat various intra-abdominal tumors, including colon cancer ([@b9-ol-0-0-4299],[@b10-ol-0-0-4299]). Intensity-modulated radiotherapy (IMRT) has been widely applied in the treatment of cancer due to its potential to provide sharp dose gradients at the junction of the tumor and the adjacent critical organs. It is considered to be safe and effective, and may be applied in the treatment of various types of cancer ([@b11-ol-0-0-4299]).

The present study reports a case of locally recurrent colon cancer, in which a radical reoperation was performed following neoadjuvant IMRT and IP chemotherapy. Written informed consent was provided by the patient for publication of this study. The study was approved by the Ethics Committee of Nanjing Drum Tower Hospital (Nanjing, China).

Case report
===========

A 28-year-old man experienced hematochezia for 6 months and was first diagnosed with sigmoid colon carcinoma by colonoscopy at the People\'s Hospital of Suqian City (Suqian, China) on June 1, 2012. The patient underwent a partial sigmoidectomy and surgical bladder repair. The pathological diagnosis was of a grade I--II adenocarcinoma of the sigmoid colon, according to Broders ([@b12-ol-0-0-4299]) carcinoma grading system, of which 50% was mucoid carcinoma. The carcinoma invaded the full-thickness of the colon wall and the muscle layer of the bladder. No lymph node metastasis was evident (0/29 nodes). The patient then underwent 6 cycles of a docetaxel combined with oxaliplatin, 5-fluorouracil and calcium folinate regimen (detailed treatment dosage data were not available). The serum levels of carcinoembryonic antigen (CEA), cancer antigen (CA)19-9, CA-125 and CA242 during the whole course were normal.

At 8 months post-adjuvant chemotherapy, the patient was presented to Nanjing Drum Tower Hospital on October 23, 2013, due to hematochezia that had persisted for several days. Laboratory tests revealed normal levels of tumor markers, including CEA, CA19-9, CA125 and CA242. Computed tomography (CT) scans revealed a mass, \~4.2 cm in diameter, at the anastomotic site, invading the bladder and the left ureter ([Fig. 1](#f1-ol-0-0-4299){ref-type="fig"}). No other metastases in the abdominal organs or lymph nodes were detected by CT. Colonoscopy biopsy revealed grade II adenocarcinoma, which was conjectured to be the result of the recurrence of the primary tumor.

The patient was treated by a multidisciplinary team, including surgeons, radiation oncologists and physicians. As the carcinoma encroached on the surrounding organs, the surgeons indicated that it was not possible to perform a radical resection and that pre-operative neoadjuvant therapy was necessary. The patient was then administered intensity modulation radiation therapy (IMRT). The planning target volume (PTV) consisted of the clinical target volume plus a 0.8 to 1-cm margin, and the PTV1 (a region of the PTV with a higher dose) consisted of the gross tumor volume plus a 0.3-cm margin. The total dose prescription for the PTV was 50 Gy and the total dose prescription for the PTV1 was 60 Gy, which were each delivered at 2 Gy per fraction ([Fig. 2](#f2-ol-0-0-4299){ref-type="fig"}). The radiotherapy was delivered over 6 weeks. Concurrent IP perfusion chemotherapy using CPT-11 (100 mg/m^2^) was administered weekly, five times during the radiotherapy course ([Fig. 2](#f2-ol-0-0-4299){ref-type="fig"}).

Following the concurrent radiation therapy and chemotherapy, CT scans revealed no evident tumor at the anastomotic site or any other metastases, indicating a clinical complete response ([Fig. 3](#f3-ol-0-0-4299){ref-type="fig"}). Subsequently, the patient underwent a second surgery to resect the remaining sigmoid colon. The pathological examination revealed no definite invasive adenocarcinoma or lymph node metastasis, thus, the patient achieved a pathological complete response (pCR) ([Fig. 4](#f4-ol-0-0-4299){ref-type="fig"}). Four additional 4-week cycles of intravenous (IV) systemic CPT-11 chemotherapy (150 mg/m^2^, days 1 and 15) combined with oral Xeloda (1,500 mg/m^2^, days 1--14) were administered. At the time of writing this study, the patient remains alive, with a disease-free survival time of \~10 months.

Discussion
==========

The majority of colon cancer local recurrences occur at 6 months to 2 years after the first surgery ([@b13-ol-0-0-4299]). While 30--40% of patients with stage II/III colon cancer experience recurrence, only 10--20% of them can undergo radical surgery ([@b14-ol-0-0-4299],[@b15-ol-0-0-4299]). It has also been reported that the 5-year survival rate may be 19--35% for patients who undergo a second radical surgery, but \<5% for inoperable patients. Radical surgery can prolong survival markedly, with the 5-year survival rate increasing up to 54%; even in patients who exhibit positive surgical margins, the 5-year survival rate can increase to 25% ([@b14-ol-0-0-4299],[@b16-ol-0-0-4299],[@b17-ol-0-0-4299]).

In the present case, the patient experienced recurrence after surgery and 6 cycles of adjuvant chemotherapy. However, according to the surgeons, the tumor could not be removed via radical surgery and so neoadjuvant medical treatment was a requisite. CPT-11, a widely used second-line anticancer agent, which has been shown to have cytotoxic activity in patients with colorectal, gastric, pancreatic, lung, ovarian, breast and cervical cancers, was chosen for application. In the liver and other tissues, carboxyl esterase converts CPT-11 to its active metabolite, SN-38, which is potently inhibits the nuclear enzyme, topoisomerase I. This enzyme exhibits cytotoxic activity that is 100--1,000-fold greater than that of CPT-11 ([@b18-ol-0-0-4299]). CPT-11 has been demonstrated to extend the overall survival of metastatic colorectal cancer patients when an IV administration ([@b19-ol-0-0-4299]). In a mouse model, IP administration of CPT-11 was significantly more effective than IV administration with regard to antitumor activity against peritoneal seeding and liver metastases ([@b20-ol-0-0-4299]). The survival benefit of IP chemotherapy has been documented in ovarian and gastric cancer, for which randomized trials showed significant a survival advantage for patients receiving IP chemotherapy ([@b21-ol-0-0-4299]--[@b23-ol-0-0-4299]). An IP CPT-11 pharmacokinetic study performed in a pig model confirmed the ability of the drug to achieve a peritoneal exposure level at least 30 times higher than that of systemic exposure. The peak concentration of peritoneal SN-38 was also achieved earlier than that of plasma SN-38, suggesting that IP infusion of CPT-11 could be an efficient route of administration in patients with abdominal carcinomas ([@b24-ol-0-0-4299]).

Unlike recurrent rectal cancer, recurrent colon cancer is not commonly treated with radiotherapy for the unfixed lesions and radioactive enteritis of the surrounding small intestines. However, technological advances in radiation treatment, particularly planning IMRT, have developed the practice, particularly for the treatment of multiple tumors, while minimizing the risk of damage to healthy tissues ([@b25-ol-0-0-4299]--[@b27-ol-0-0-4299]). IMRT has been applied to treat recurrent colon cancer according to the National Comprehensive Cancer Network treatment guidelines ([@b28-ol-0-0-4299]). In the present study, prior to receiving the treatment, the patient expressed a strong desire to undergo an anus-preserving procedure, which is difficult to achieve surgically. The patient later refused to undergo a second surgery and a radiotherapy plan was formulated with the aim of a radical cure. However, at the end of radiotherapy, the patient decided to undergo the required surgery. The post-operative pathological result revealed a pCR following neoadjuvant therapy, which usually occurs at a low rate, but allows for improved survival times. It has been reported that the cumulative 5-year survival rates may reach 75% for patient with a pCR ([@b29-ol-0-0-4299],[@b30-ol-0-0-4299]).

In conclusion, in the present case, a patient with recurrent colon cancer was effectively treated by a multidisciplinary treatment that included IMRT, IP perfusion chemotherapy and a second surgery. A pCR was achieved, indicating that IMRT combined with IP perfusion chemotherapy using CPT-11 may be a feasible neoadjuvant therapy for recurrent colon cancer.
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